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ess: kazumak@toranomSummary The objective of this study was to clarify clinical and high-resolution
computed tomography (HRCT) characteristics in non-AIDS patients with pulmonary
cryptococcosis. We analyzed the medical records and HRCT scans in 22 patients with
pulmonary cryptococcosis from 1988 to 2003. Thirteen patients (59%) were immuno-
competent and nine (41%) were immunosuppressed, seven of whom had diabetes
mellitus. No patients exhibited extrapulmonary involvement. Nineteen patients (86%)
were asymptomatic. Radiography revealed incidental chest abnormality in all but two
patients. The typical HRCT findings were solitary or multiple nodules in the subpleural
area. Cavitation was present in 30% of the patients who had nodules. The most
frequently applied and reliable diagnostic procedure was video-assisted thoracoscopic
surgery (VATS). Treatment included antifungal therapy alone in 11 patients, surgery
alone in eight including four treated by VATS, surgery plus antifungal therapy in two and
none in one. Patients who underwent surgery alone did not develop any relapse. The
majority of non-AIDS patients with pulmonary cryptococcosis present with incidental
chest radiographic abnormalities. The most common HRCT findings are solitary or
multiple nodules with or without cavitation in the subpleural areas of the lung. VATS is a
useful tool for both diagnosis and treatment of isolated pulmonary cryptococcosis.
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Cryptococcosis is an illness caused by infection with
the encapsulated fungus, Cryptococccus neofor-
mans, an organism with a worldwide distribution.1
Inhalation of organisms is the usual route of
infection that may remain isolated to the lungs or
undergo hematogenous spread to involve the
central nervous system (CNS), bones, and skin,
depending on the host immune status.
Cryptococcal infection can occur in individuals
with normal immunity but is most common in the
immunocompromised host.1,2 Predisposing factors
include acquired immunodeficiency syndrome
(AIDS), hematologic malignancies, organ transplan-
tation, corticosteroid therapy, diabetes mellitus,
and other conditions that impair T-cell mediated
immunity. In particular, cryptococcosis is most
prevalently associated with AIDS patients.3
The clinical features and computed tomography
(CT) findings of pulmonary cryptococcosis in non-
AIDS individuals have not been well described
because cryptococcal infections among these sub-
jects are quite rare. The most common radio-
graphic characteristics are known as solitary or
multiple pulmonary nodules or masses.4–6 Other
less frequent radiographic features may include
segmental or lobar pneumonia, cavitation, lympha-
denopathy or pleural effusion. However, there is
only a limited number of studies focusing on CT
findings of pulmonary cryptococcosis in non-AIDS
individuals.7–9 In immunocompromised patients,
pulmonary cryptococcosis should be treated with
antifungal therapy.10 In contrast, there are several
therapeutic options such as follow-up observation,
antifungal therapy or surgical resection of the
lesion in immunocompetent patients.2,4,10–13
In Japan, because of mass screening or the
widespread use of chest CT, the number of
detected patients with pulmonary cryptococcosis
is increasing.14 The histologic diagnosis of pulmon-
ary cryptococcosis can be made more easily than
ever by the recent development of video-assisted
thoracoscopic surgery (VATS). The aim of this study
was to clarify clinical features and high-resolution
CT (HRCT) findings in non-AIDS individuals with
pulmonary cryptococcosis.Materials and methods
We reviewed 22 individuals with pulmonary crypto-
coccosis in a non-AIDS condition who were treated
in Toranomon Hospital from June 1988 through
October 2003. The diagnosis of pulmonary crypto-coccosis was confirmed by histologic presence of
the organism in a lung biopsy specimen or a positive
finding from culturing respiratory specimens or
positive result of the serum cryptococcal antigen
test with a radiographic evidence of pulmonary
disease.
The medical charts, HRCT images and histologic
specimens were reviewed. From the medical
charts, the following data were abstracted: age,
sex, smoking history, underlying disease, respira-
tory symptoms, serum cryptococcal antigen, data
for cerebrospinal fluid (CSF), and finally, treatment
and follow-up information.
CT scans were performed on CT 9800 scanner or
High Speed Advantage scanner (GE Medical Sys-
tems, Milwaukee, USA). Routine scanning of the
entire lung was carried out with 10-mm section
thickness. Additional HRCT scans with 1–3mm
collimation were acquired through areas of interest
with a bone algorithm using fixed window settings
(lung center, 500HU and width, 1800HU) from all
patients.
A consensus reading of the HRCT images was
conducted by two observers (A.K., K.K.). CT
findings were divided into two categories: nodules
or consolidation. Nodules were classified according
to predominant size (1–5, 6–10, 11–29mm), num-
ber (1, 2–4, 5–10, or 410), margination (smooth,
irregular, well defined, ill defined, lobulation,
spiculation, convergency of peripheral bronchi
and vessels, or pleural indentation) and internal
characteristics (cavitation, air-bronchogram, or
calcification).
The lobar distribution of parenchymal lesions was
evaluated and the locations were also categorized
into a central or a peripheral type by an imaginary
line of 3 cm apart from the pleura.
All resected specimens were stained with hema-
toxylin–eosin, Grocott, and periodic acid-Schiff,
and reviewed by one pulmonary pathologist (N.M.).Results
Clinical characteristics of 22 patients with pulmon-
ary cryptococcosis are summarized in Table 1.
Seventeen individuals were male and five were
female, with a mean age of 54.5 years. Sixteen
patients (73%) were non-smokers. Four were past
and two were current smokers, with a mean of 21
pack-years. Only one patient had a close contact
with pigeons that frequently flew to the veranda
of his residence. Thirteen patients were immuno-
competent and nine were immunosuppressed.
Seven of nine immunocompromised patients had
diabetes mellitus. Three patients were receiving
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Table 1 Clinical characteristics of 22 patients
with pulmonary cryptococcosis.
Characteristics Subjects (%)
Age, yr
Mean 54.5
Range 24–85
Gender
Male 17 (77)
Female 5 (23)
Host status
Immunocompetent 13 (59)
Immunocompromised 9 (41)
Immunocompromising conditions
Diabetes mellitus 6
Diabetes mellitus+bronchial
asthma
1
Autoimmune pancreatitis 1
Non-Hodgkin’s lymphoma 1
Corticosteroid therapy 3
Symptoms
None 19 (86)
Cough and fever 1
Cough 1
General fatigue 1
Mode of detection
Mass screening 15 (68)
Routine follow-up of other
diseases
5 (23)
Subjective symptoms 2 (9)
Table 2 HRCT findings of pulmonary nodules in 20
patients of pulmonary cryptococcosis.
Characteristics Subjects (%)
Number of nodules
Solitary 12 (60)
Multiple 8 (40)
5–10 3 (15)
410 5 (25)
Nodular margin
Well defined 17 (85)
Poorly defined 5 (15)
Irregular 12 (70)
Smooth 6 (30)
Spiculation 6 (30)
Lobulation 7 (35)
Convergence of peripheral
vessels and bronchi
10 (50)
Pleural indentation 10 (50)
Internal characteristics
Cavity 6 (30)
Air-bronchogram 7 (35)
Figure 1 An immunocompetent patient with pulmonary
cryptococcosis. (A) HRCT scan shows a spiculated nodule
with pleural indentation resembling well-differentiated
adenocarcinoma. (B) Photomicrograph of the lower
magnification shows a cluster of granulomas with irregular
margin (hematoxylin–eosin stain). The bar indicates 5mm.
(C) Photomicrograph of the higher magnification reveals
caseous epithelioid cell granuloma (hematoxylin–eosin
stain). The bar indicates 100mm.
HRCT findings of pulmonary cryptococcosis 809corticosteroid therapy. Nineteen patients (86%)
were asymptomatic. As the mode of detection, 15
patients were incidentally detected an abnormal
radiographic findings on mass screening. All pa-
tients had pulmonary cryptococcosis without
any extrapulmonary involvement, and no progres-
sive dissemination occurred during the follow-up
period.
CSF was examined in five patients (23%), and the
findings of Indian ink and culture were all negative.
Five of 14 patients (36%) revealed positive for the
serum cryptococcal antigen. According to the host
status, the serum cryptococcal antigen was positive
in two of six immunocompetent patients (33%) and
three of eight immunocompromised patients (38%).
HRCT patterns included pulmonary nodules in 20
of 22 patients (91%) (Table 2) and consolidation in
two patients, respectively. The number of nodules
in each case was one in 12 patients, 5–10 in three,
and more than 10 in five (Figs. 1 and 2). The
diameter ranges of the multiple pulmonary nodules
were less than 6mm in four patients, 6–10mm in
two, and more than 10mm in two. Margination ofnodules in each patient was well defined in 17
(85%), irregular in 12 (60%), and spiculated in six
(30%), respectively. Cavitation was seen in six
patients (30%). According to the host status,
cavitation was present in 2 of 12 immunocompetent
patients (17%) and in four of eight immunocompro-
mised patients (50%) (Fig. 2). Ground-glass opa-
cities were found as an associated finding with
nodules in three patients. Consolidation was iden-
tified as the predominant CT finding in two patients
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Figure 2 A diabetic patient with pulmonary cryptococ-
cosis. (A) HRCT scan shows well demarcated mass with
cavitation and small nodules mimicking tuberculosis.
(B) Photomicrograph of the lower magnification reveals
encapsulated epithelioid cell granuloma with central
cavitation (hematoxylin–eosin stain). The bar indicates
5mm. (C) Cryptococci are found in the necrotic tissue
(Grocott stain). The bar indicates 100 mm.
Figure 3 Chest CT scan of a symptomatic patient with
pulmonary cryptococcosis who had no underlying disease.
Note the patchy areas of air-space consolidation with air-
bronchograms, and adjacent ground-glass opacities in the
subpleural region in the right lower lobe.
K. Kishi et al.810(one immunocompetent and one immunocompro-
mised) with ground-glass opacities (Fig. 3). Lower
lobes were involved in 14 patients (64%) and upperlobes in four (18%). Diffuse nodular lesions were
found in four patients (18%). Parenchymal lesions
were located in the peripheral portion in 20
patients (91%), 14 of which had contact with the
pleura.
The diagnosis of pulmonary cryptococcosis was
made by direct tissue examination in 18 patients
(surgery in 13, percutaneus needle biopsy in four,
and transbronchial biopsy in one), and by culture of
the organism from bronchial lavage fluid in two and
a percutaneus needle biopsy specimen in one. An
immunocompetent patient presented with cough
was diagnosed as having pulmonary cryptococcosis
based on a positive cryptococcal antigen titer and
histologic findings of epithelioid cell granuloma
formation (Fig. 3). Among 13 patients who under-
went surgery, thoracoscopic excisional biopsy was
performed in nine patients (41%).
Treatment included antifungal therapy alone in
11 patients, surgery alone in eight patients, surgery
plus antifungal therapy in two and none in one. Of
11 patients (five immunocompetent and six im-
munocompromised) treated with an antifungal
agent alone, itraconazole was prescribed in eight
patients, fluconazole in two and amphotericin B
syrup plus 5-flucytosine in one. The duration of
treatment ranged from 1.8 to 27.5 months with a
median of 5.1 months for five immunocompetent
patients, and 6.0 to 24.3 months with a median of
9.3 months for six immunocompromised patients.
Radiographic findings showed improvement in all
patients. The follow-up period after antifungal
therapy ranged from 2.4 to 172.5 months, with a
median of 8.7 months. CT findings revealed
deterioration in an immunocompetent patient
who had multiple cavitary nodules 22 months after
discontinuation of itraconazole. The patient was
re-treated with itraconazole for 10 months and
multiple nodules improved one more time.
Eight patients including seven immunocompetent
ones underwent surgical resection because the
diagnosis had not been confirmed preoperatively.
Open lung surgery was performed in four patients
and VATS in four. The procedure of surgery was
wedge resection in seven and lobectomy in one.
The follow-up period after surgery ranged 10.1 to
177.7 months, with a median of 42.4 months. No
relapse was seen after surgery.
Two patients received both antifungal therapy
and surgical resection. One individual underwent
wedge resection after antifungal therapy, and no
recurrence has been observed for 23.3 months.
Another patient who had both diabetes mellitus
and bronchial asthma was treated with amphoter-
icin B plus 5-flucytocine for 2 months and surgery
was performed. Subsequently, fluconazole was
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HRCT findings of pulmonary cryptococcosis 811administered for 10 months, but pulmonary cryp-
tococcosis relapsed thereafter. Fluconazole was re-
administered for 13 months, followed by itracona-
zole for 45 months. Antifungal therapy lasted long
because the patient eventually developed pulmon-
ary infiltration with eosinophilia and was treated
with corticosteroid therapy. Fortunately, no relapse
occurred for 5 years after antifungal therapy.
One patient was followed up without any therapy
for 3 months because of spontaneous resolution of
the radiographic findings.Discussion
Clinical description regarding pulmonary crypto-
coccosis with non-AIDS individuals is rather limited
because of the rarity of the disease itself. In
general, men are involved more frequently than
women.2 Likewise, in the present study, the disease
was overwhelmingly predominant in males. As has
been reported in a recent study, about one-third of
immunocompetent patients with pulmonary cryp-
tococcosis were asymptomatic.13 Most of our
patients were also asymptomatic and incidentally
detected on chest radiographs taken at mass
screening or on the routine follow-up of other
diseases. About 40% of the patients were immuno-
suppressed, and diabetes mellitus was the most
common underlying disease.
Although the radiographic characteristics of
pulmonary cryptococcosis have been well de-
scribed, there are only a few studies evaluating
the CT findings in non-AIDS individuals thus far.7–9
Zinck et al.7 demonstrated that the most common
CT finding was solitary or multiple pulmonary
nodules without cavitation in 10 (91%) of 11 cases.
The margination of nodules was smooth in five
cases. Similarly, our study demonstrated that
pulmonary nodules were the most frequent HRCT
findings of pulmonary cryptococcosis. However,
irregular margin and spiculation were observed in
70% and 30% of the patients who had nodules,
respectively. Cavitation inside the nodule has been
reported to be a less common radiographic finding
and limited to immunocompromised patients.5,15 In
the present study, cavitation was found in 30% of
the patients with nodular lesions, especially in half
of the immunocompromised patients. In this con-
text, it may be quite difficult to distinguish a
spiculated nodule from lung cancer and a cavitary
nodule from tuberculosis. Lindell et al.9 examined
CT findings of pulmonary cryptococcosis in 10
immunocompetent patients recently and, as in
our study, found that pulmonary nodules were themost common CT findings, although the majority of
their patients had multiple nodules as oppose to
those in our study. Similar to the findings about the
size of multiple nodules in our study, the nodules
were most commonly less than 10mm in diameter. In
contrast to our observations, the majority of nodules
was well defined with smooth margins, and area of
cavitation occurred less frequently in their study
Regarding the distribution of the lesions of
pulmonary cryptococcosis, no particular lobar pre-
dilection of the disease has been noted,2,5,7,8
although Hatcher et al.4 demonstrated the pre-
dominance in the lower lobes. Likewise, in the
present study, the lower lobes were affected more
frequently than the upper lobes. In addition, the
nodules were usually located in the subpleural
regions, as described in the previous reports.6,8
The treatment of pulmonary cryptococcosis de-
pends on the hosts’ immune status and the anatomi-
cal sites of involvement. Practical guidelines for the
management of cryptococcal disease by Saag et al.10
recommended observation alone for immunocompe-
tent hosts with isolated pulmonary cryptococcosis
and antifungal therapy for those with symptomatic
infection. Preferred treatment regimens are oral azol
therapy (fluconazole or itraconazole) for 6–12
months. HIV-negative, immunocompromised patients
with the non-CNS pulmonary and extrapulmonary
disease are recommended to be treated with
amphotericin B plus flucytosine for 6–10 weeks as
patients with the CNS disease.
We hence treated immunocompetent as well as
immunocompromised patients of proven pulmonary
cryptococcosis with antifungal therapy if there was
no radiographic resolution after a 1–2-month
period of close observation. Radiographic findings
revealed improvement in all patients treated with
oral azole antifungal agents alone without side
effects, even in the immunocompromised hosts.
For focal pulmonary cryptococcosis, surgical resec-
tion is a choice of treatment if preoperative diagnosis
cannot be confirmed.4,13 Recently, small peripheral
nodules have frequently been detected by CT scans,
and VATS is used to make precise diagnosis for such
lesions.16,17 To our knowledge, however, no studies
have proved the efficacy of VATS in the diagnosis and
treatment of pulmonary cryptococcosis. In the
present study with the use of VATS, nine patients
were diagnosed as having pulmonary cryptococcosis,
and four patients underwent wedge resection under
VATS. No relapse occurred. Because the lesions of
pulmonary cryptococcosis are usually located in the
subpleural area of the lung and are of a benign
nature, wedge resection under VATS could be a
reasonable and a possibly ideal option for non-AIDS
patients with isolated pulmonary cryptococcosis.
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with pulmonary cryptococcosis are males. They are
commonly asymptomatic and are found to have
incidental chest radiographic abnormalities. The
most common HRCT findings are solitary or multiple
nodules with or without cavitation in the subpleural
areas of the lung. The nodules so often resemble
lung cancer or tuberculosis, that histologic con-
firmation is required. In this regard, VATS is a useful
tool for both diagnosis and treatment of isolated
pulmonary cryptococcosis.References
1. Wheat LJ, Goldman M, Sarosi G. State-of-the-art review of
pulmonary fungal infections. Semin Respir Infect 2002;
17:158–81.
2. Kerkering TM, Duma RJ, Shadomy S. The evolution of
pulmonary cryptococcosis. Clinical implications from a study
of 41 patients with and without compromizing host factors.
Ann Intern Med 1981;94:611–6.
3. Chuck SL, Sande MA. Infections with Cryptococcus neofor-
mans in the acquired immunodeficiency syndrome. N Engl J
Med 1989;321:794–9.
4. Hatcher Jr CR, Sehdeva J, Waters WC, et al. Primary
pulmonary cryptococcosis. J Thorac Cardiovasc Surg 1971;
61:39–49.
5. Gordonson J, Birnbaum W, Jacobson G, Sargent EN.
Pulmonary cryptococcosis. Radiology 1974;112:557–61.
6. Woodring JH, Ciporkin G, Lee C, Worm B, Woolley S.
Pulmonary cryptococcosis. Semin Roentgenol 1996;31:67–75.7. Zinck SE, Leung AN, Frost M, Berry GJ, Mu¨ller NL. Pulmonary
cryptococcosis: CT and pathologic findings. J Comput Assist
Tomogr 2002;26:330–4.
8. Lacomis JM, Costello P, Vilchez R, Kusne S. The radiology of
pulmonary cryptococcosis in a tertiary medical center.
J Thorac Imaging 2001;16:139–48.
9. Lindell RM, Hartman TE, Nadrous HF, Ryu JH. Pulmonary
cryptococcosis. CT findings in immunocompetent patients.
Radiology 2005;236:326–31.
10. Saag MS, Graybill RJ, Larsen RA, et al. Practical guidelines
for the managemnet of cryptococcal disease. Clin Infect Dis
2000;30:710–8.
11. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococ-
cosis in patients without HIV infection. Chest 1999;115:
734–40.
12. Nu´n˜ez M, Peacock Jr JE, Chin Jr R. Pulmonary cryptococcosis
in the immunocompetent host. Therapy with oral flucona-
zole: a report of hour cases and a review of the literature.
Chest 2000;118:527–34.
13. Nadrous HF, Antonios VS, Terrell CL, Ryu JH. Pulmonary
cryptococcosis in nonimmunocompromised patients. Chest
2003;124:2143–7.
14. Ishiguro M, Yoshida R, Miura N, et al. Study on pulmonary
cryptococcosis disclosed by chest radiographic screening in
Nagasaki prefecture. Nihon Kokyuki Gakkai Zasshi 2000;
38:903–7 abstract in English.
15. Khoury MB, Godwin JD, Ravin CE, Gallis HA, Halvorsen RA,
Putman CE. Thoracic cryptococcosis: immunologic compe-
tence and radiologic appearance. AJR 1984;141:893–6.
16. Swensen SJ, Jett JR, Sloan JA, et al. Screening for lung
cancer with low-dose spiral computed tomography. Am J
Respir Crit Care Med 2002;165:508–13.
17. Kishi K, Homma S, Kurosaki A, et al. Small lung tumors with
the size of 1 cm or less in diameter: clinical, radiological,
and histopathological characteristics. Lung Cancer 2004;44:
43–51.
